advertisement
A study conducted in collaboration with National Institute of Virology and Indian Council of Medical Research, by peer-review medical journal Clinical Infectious Diseases, has noted that Bharat Biotech’s Covaxin demonstrates protection against the new COVID-19 variants.
Published in the Oxford journal, the study found that vaccination with Covaxin produced neutralising titres against all key emerging variants tested including B.1.617 and B.1.1.7, first identified in India and the UK, respectively.
Bharat Biotech joint managing director Suchitra Ella cited the study in a tweet and said, “COVAXIN neutralising emerging variants”.
The study also observed a modest reduction in neutralisation by a factor of 1.95 against B.1.617 variant compared to vaccine variant.
No difference in neutralisation between B.1.1.7 (first isolated in the UK) and vaccine strain (D614G) was observed.
(At The Quint, we question everything. Play an active role in shaping our journalism by becoming a member today.)